Note: This story was updated Jan. 20, 2026, to clarify that the label update also removed age restrictions, allowing Cerezyme to be used from birth. The U.S. Food and Drug Administration (FDA) has expanded the approval of Cerezyme (imiglucerase) to include the treatment of non-neurological symptoms in children…
Expectant parents can now screen for a broader range of inherited conditions, including Gaucher disease, using only a maternal blood sample and Natera‘s updated Fetal Focus test. The update adds 16 new genes to the panel, enabling the screening of a total of 21 genetic diseases early in…
Switching patients who are doing well on their current Gaucher disease treatment to a different medication comes with risks, and it may be “inappropriate” for health insurers to require a change to cut costs, according to a study from Quebec. Gaucher disease patients who switched their enzyme…
